List of Excipients in Branded Drug GIAPREZA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
La Jolla Pharmaceutical Company	GIAPREZA	angiotensin ii	68547-501	HYDROCHLORIC ACID
La Jolla Pharmaceutical Company	GIAPREZA	angiotensin ii	68547-501	MANNITOL
La Jolla Pharmaceutical Company	GIAPREZA	angiotensin ii	68547-501	SODIUM HYDROXIDE
La Jolla Pharmaceutical Company	GIAPREZA	angiotensin ii	68547-501	WATER

Last updated: August 20, 2026

Giapreza excipient strategy is deliberately conservative: angiotensin II acetate is supplied as a sterile, concentrated solution with mannitol, polysorbate 80, hydrochloric acid, and water for injection. The largest commercial opportunity is not a new active ingredient formulation. It is a hospital-ready presentation that reduces dilution steps, minimizes vial waste, improves infusion-pump workflow, and preserves stability and compatibility in intensive-care settings.

What is Giapreza and how is it formulated?

Giapreza is the brand name for synthetic human angiotensin II, marketed by La Jolla Pharmaceutical Company, an Innoviva company. The FDA approved Giapreza on December 21, 2017, for increasing blood pressure in adults with septic or other distributive shock who remain hypotensive despite adequate volume and catecholamine therapy.[1]

The approved product is a sterile intravenous injection with a 2.5 mg/mL angiotensin II acetate concentration in a 1 mL single-dose vial.

Product attribute	Giapreza specification
Active ingredient	Angiotensin II acetate
Strength	2.5 mg/mL
Container	1 mL single-dose vial
Route	Intravenous infusion after dilution
Principal excipients	Mannitol, polysorbate 80, hydrochloric acid, water for injection
Primary setting	Intensive care and hospital critical-care units
FDA approval	December 21, 2017
Indication	Vasodilatory shock in adults
Initial recommended dose	20 ng/kg/min
Titration	5 to 15 ng/kg/min increments at intervals of at least 5 minutes
Maximum dose	80 ng/kg/min
Dilution	Diluted before intravenous infusion
Post-dilution use	Label-controlled storage and administration conditions apply

The formulation uses mannitol as a tonicity and bulking component and polysorbate 80 as a surfactant. Hydrochloric acid is used for pH adjustment. The composition does not rely on a complex delivery system, lipid carrier, polymer depot, or lyophilized presentation.[1]

What excipients protect Giapreza stability and usability?

Mannitol

Mannitol provides tonicity control and may help maintain an acceptable solution environment for the peptide. It is a familiar injectable excipient with broad hospital use and an established regulatory history.

Its commercial value is practical rather than differentiating. Mannitol supports a simple liquid formulation that avoids reconstitution and reduces the operational burden associated with lyophilized peptides.

Key risks include:

• Concentration-dependent osmolality changes after dilution.
• Potential precipitation or compatibility issues in nonvalidated diluents.
• Increased formulation complexity if the product is concentrated further.
• Need for tight control of particulate matter and visible appearance.

Polysorbate 80

Polysorbate 80 protects against surface adsorption and aggregation of the peptide during manufacturing, storage, and infusion preparation. This is particularly relevant for a low-dose biologically active peptide administered through bags, tubing, filters, and infusion-pump assemblies.

Polysorbate 80 also creates the main excipient risk area:

• Peroxide and degradation products can increase during storage.
• Trace impurities can affect peptide stability.
• Surfactant concentration must be controlled to avoid unnecessary exposure.
• Container, stopper, tubing, and filter interactions require extractables and leachables assessment.

A differentiated commercial formulation could reduce polysorbate exposure, replace it with another surfactant, or use a more robust container-closure system. Any such change would require comparative stability, aggregation, subvisible particle, adsorption, and infusion-line compatibility data.

Hydrochloric acid

Hydrochloric acid is used to adjust formulation pH. Its role is narrow but important. Angiotensin II is a peptide, and pH affects solubility, aggregation, chemical degradation, and adsorption behavior.

A revised formulation would need to establish:

• pH range at release and throughout shelf life.
• Peptide purity and related-substance profile.
• Aggregate and subvisible-particle control.
• Compatibility with diluted infusion solutions.
• Stability after transfer to common hospital containers.

Water for injection

Water for injection is the vehicle. The product's commercial simplicity depends on maintaining a clear, sterile, low-particulate liquid while preserving potency at a very low administered dose.

What is the current FDA regulatory status of Giapreza?

Giapreza is an FDA-approved prescription product under NDA 209360.[1] The label identifies it as a concentrated solution that must be diluted before infusion. The formulation is not a pre-mixed, ready-to-administer infusion bag.

The FDA approval was based primarily on the ATHOS-3 clinical study, which evaluated intravenous angiotensin II in patients with vasodilatory shock who required vasopressors. Angiotensin II produced a higher rate of blood-pressure response than placebo at the prespecified endpoint.[2]

The regulatory pathway for a new Giapreza presentation would depend on the extent of formulation and manufacturing changes:

Proposed change	Likely regulatory treatment
New vial size with unchanged composition	Supplement or manufacturing change, depending on scope
Ready-to-use infusion bag	Likely supplemental NDA with new container, concentration, stability, and administration data
New excipient or materially changed excipient level	Comparative pharmaceutical development and stability package
New concentration	Dose-delivery, safety, compatibility, and human-factors assessment
New route or delivery device	Potentially extensive clinical and device combination-product review
Generic injectable copy	ANDA pathway if sameness and legal requirements are met

The most attractive development path is a line extension that preserves the approved active ingredient and clinical use while improving hospital preparation.

What formulations are protected by Giapreza's commercial and regulatory position?

The approved formulation protects more than the ingredient concentration. A competitive product must address the complete injectable-product package:

1. Angiotensin II acetate identity and potency.
2. Sterile liquid manufacturing.
3. Peptide aggregation and degradation control.
4. Surfactant and excipient quality.
5. Container-closure integrity.
6. Dilution stability.
7. Infusion-line adsorption and compatibility.
8. Particulate and endotoxin limits.
9. Accurate low-dose administration.
10. Label-compliant preparation and storage.

The formulation itself appears technically straightforward, but injectable peptide products can have meaningful manufacturing barriers. The main barrier is reproducible quality at commercial scale, not the number of excipients.

A formulation patent could focus on:

• Specific angiotensin II concentrations.
• Defined pH and osmolality windows.
• Surfactant systems.
• Low-peroxide polysorbate specifications.
• Container-closure materials.
• Diluted infusion stability.
• Ready-to-use bags.
• Compatibility with tubing, filters, and pumps.
• Reduced adsorption during continuous infusion.
• Manufacturing controls for peptide-related impurities.

Patent value would depend on claim breadth, written-description support, prosecution history, and whether a competing product can design around the claimed excipient ratios or packaging configuration. FDA approval alone does not establish the scope of patent protection.

When does Giapreza lose exclusivity and what generic entry risks exist?

Giapreza's loss-of-exclusivity analysis requires separate review of FDA regulatory exclusivity, Orange Book-listed patents, pediatric exclusivity, and any applicable litigation or settlement activity.

The FDA approval date was December 21, 2017. That date alone does not determine the end of all commercial protection. A five-year new chemical entity period, if applicable, would be analytically separate from patent expiry and would not necessarily prevent every form of competing product indefinitely.[1]

For generic-entry analysis, the relevant questions are:

• Whether the product has Orange Book-listed patents.
• Whether a potential ANDA applicant can file a Paragraph IV certification.
• Whether the proposed generic uses the same active ingredient form.
• Whether the generic matches the approved strength and route.
• Whether formulation or manufacturing patents are listed.
• Whether the reference product has unexpired regulatory exclusivity.
• Whether litigation triggers a 30-month stay.
• Whether a settlement restricts or permits an agreed launch date.

A generic injectable could face a lower technical barrier than a complex biologic, but it would still need to demonstrate pharmaceutical equivalence, sterility, stability, particulate control, and reliable administration at very low doses.

How strong is the Giapreza excipient and manufacturing patent estate?

The commercial strength of Giapreza's formulation position is likely to depend more on manufacturing know-how and clinical workflow integration than on excipient novelty alone.

Stronger protection areas

• Peptide purity and impurity control.
• Stable sterile liquid manufacture.
• Low-concentration dilution behavior.
• Container and infusion-line compatibility.
• Ready-to-use presentations with validated shelf life.
• Device-assisted dose administration.
• Hospital preparation and storage instructions.
• Narrow formulation claims tied to measurable stability outcomes.

Weaker protection areas

• Mannitol as a conventional tonicity agent.
• Polysorbate 80 as a conventional peptide surfactant.
• Water for injection.
• Generic pH adjustment with hydrochloric acid.
• Broad claims covering standard intravenous dilution.

A formulation strategy based only on the existing excipient identities would likely provide limited freedom-to-operate protection. More defensible intellectual property would connect the excipient system to a measurable technical result, such as reduced aggregation, reduced adsorption, longer room-temperature stability, or improved compatibility with infusion equipment.

What commercial opportunities exist for Giapreza excipient innovation?

Ready-to-use infusion bags

The largest opportunity is a premixed, ready-to-administer bag. Current vial-based preparation creates multiple hospital steps:

• Vial withdrawal.
• Diluent selection.
• Bag labeling.
• Concentration calculation.
• Pump programming.
• Beyond-use-time management.
• Wastage control.

A premixed bag could reduce compounding errors and shorten time to administration. The principal development issues are concentration selection, shelf life, bag material, overfill, extractables and leachables, and protection from adsorption to the infusion set.

Potential presentations could include a standard adult-use concentration and a higher-concentration option for fluid-restricted patients. A higher concentration may reduce fluid burden but would increase the consequences of dose-programming errors.

Smaller-dose and pediatric-oriented presentations

Giapreza is approved for adults. A smaller vial or low-volume presentation could support weight-based dosing and reduce wastage in lower-weight patients or investigational pediatric use.

This opportunity would require more than a new vial size if the target population or indication changes. Pediatric development could trigger additional clinical, dosing, palatability, safety, and regulatory requirements even though the product is intravenous.

Low-adsorption administration systems

Angiotensin II is administered at nanogram-per-kilogram-per-minute rates. At these concentrations, adsorption to bags, tubing, filters, and connectors can materially affect delivered dose.

A product paired with validated low-binding tubing or a dedicated administration set could create a defensible commercial package. The value proposition would be strongest if the sponsor demonstrates improved dose recovery and reduced preparation variability.

Extended post-dilution stability

The label-controlled post-dilution handling period limits hospital flexibility. A formulation or packaging system that extends stability could reduce pharmacy workload and product waste.

A credible claim would require real-time and accelerated stability data covering:

• Potency.
• Degradation products.
• Aggregates.
• Particulates.
• Sterility assurance.
• Container interaction.
• Infusion-line recovery.
• Multiple diluents and temperatures.

Cold-chain reduction

A more robust formulation could support less restrictive storage or longer room-temperature exposure. This would be commercially useful for emergency departments, transport teams, and hospitals with decentralized pharmacy operations.

The opportunity is meaningful only if the product maintains quality during temperature excursions common in hospital logistics.

Combination hospital contracting

An improved Giapreza presentation could be bundled into a critical-care portfolio with vasopressors, infusion devices, pharmacy services, and emergency stock programs. The commercial buyer is often the hospital system or group purchasing organization rather than the individual prescriber.

An excipient change that produces only a modest laboratory benefit may have limited purchasing impact. A product that reduces preparation time, waste, dosing errors, or nursing workload has a clearer procurement case.

How does Giapreza compare with competing vasopressors?

Giapreza occupies a specialized position in vasodilatory shock. Norepinephrine remains the standard first-line vasopressor in septic shock guidance, while vasopressin and epinephrine are commonly used adjunctively. Angiotensin II is generally considered when hypotension persists despite conventional vasopressor therapy.[2,3]

Attribute	Giapreza	Norepinephrine	Vasopressin
Active mechanism	Angiotensin II receptor agonism	Alpha-adrenergic vasoconstriction	V1 receptor agonism
Typical role	Rescue or adjunctive vasopressor	First-line vasopressor	Adjunctive vasopressor
Product complexity	Concentrated peptide injection	Established injectable products	Established injectable products
Main formulation opportunity	Ready-to-use bag, low adsorption, stability	Convenience and premix competition	Premix and standardized concentration
Key commercial barrier	Cost, clinical positioning, preparation workflow	Broad familiarity and low cost	Established ICU protocols
Generic competition	Injectable peptide equivalence and formulation challenges	Extensive generic competition	Extensive generic competition

Giapreza's excipient opportunity is strongest where the product can reduce the operational disadvantages of a specialized rescue therapy.

Which companies are challenging Giapreza?

Publicly visible competition is more likely to arise from established vasopressor manufacturers and generic injectable companies than from direct peptide-formulation competitors.

The potential competitor groups are:

• Generic injectable manufacturers assessing an ANDA pathway.
• Critical-care companies developing premixed vasopressor products.
• Hospital pharmacy suppliers offering compounded or outsourced preparations.
• Device companies integrating vasopressor delivery with infusion systems.
• Sponsors developing alternative shock therapies.

A generic challenge would be most commercially credible if the applicant can match the reference product's concentration, excipient profile, stability, and administration requirements without infringing listed patents.

What litigation and settlement issues affect Giapreza?

Paragraph IV risk depends on the current Orange Book listing and any Abbreviated New Drug Application certifications. A complete litigation assessment must track:

• Patent numbers listed for NDA 209360.
• ANDA filing dates.
• Paragraph IV notices.
• District court complaints.
• Preliminary injunctions.
• 30-month stay dates.
• Settlement terms.
• Agreed generic launch dates.
• Federal Circuit appeals.

The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity information.[4] Innoviva's SEC filings and court dockets are the relevant sources for commercial and litigation developments.[5]

For a formulation-focused investor or licensee, the most important distinction is whether a challenger can copy the marketed dosage form without copying a protected manufacturing or stability claim.

What licensing opportunities exist around Giapreza excipients?

Licensing opportunities fall into four categories.

Ready-to-use presentation licensing

A formulation owner could license a premixed bag technology to the Giapreza commercial rights holder. The deal would likely require ownership or access to stability, packaging, and hospital-use data.

Surfactant and peptide-stabilization technology

A supplier with a low-peroxide surfactant, alternative nonionic surfactant, or peptide-stabilizing excipient could pursue a platform license. The commercial case would require demonstrated superiority over conventional polysorbate 80.

Container and administration technology

Low-binding bags, tubing, filters, and connectors could be licensed as a combination product or co-packaged administration system. This path may be more practical than changing the core formulation.

Contract manufacturing

A specialized sterile-peptide manufacturer could offer scale-up, aseptic filling, analytical release testing, and container-closure expertise. The value would be highest if the manufacturer has validated methods for aggregation, adsorption, and low-level impurity analysis.

What revenue exposure does Giapreza create for an excipient supplier?

Giapreza is a hospital product used in a relatively narrow but high-acuity indication. Demand is driven by ICU admissions, refractory vasodilatory shock, protocol adoption, formulary decisions, and payer economics.

An excipient supplier should not value the opportunity as a mass-market injectable. The commercial case is based on:

• High clinical consequence of dose delivery.
• Need for sterile injectable quality.
• Potential premium for reduced preparation burden.
• Recurring hospital demand.
• Switching costs once protocols and pharmacy standards are established.
• Potential expansion into additional shock indications.

The most attractive supplier position is an excipient or container technology that is difficult to substitute and can be incorporated without changing the approved active ingredient or clinical use.

Key Takeaways

• Giapreza contains angiotensin II acetate in a concentrated sterile liquid formulation.
• Mannitol, polysorbate 80, hydrochloric acid, and water for injection support tonicity, peptide stability, pH control, and injectability.
• The strongest commercial opportunity is a ready-to-use infusion bag or validated low-adsorption administration system.
• A new excipient strategy must demonstrate measurable gains in stability, dose recovery, compatibility, or workflow efficiency.
• Conventional excipient identities alone are unlikely to create a strong standalone patent position.
• Generic-entry risk depends on Orange Book listings, Paragraph IV activity, formulation sameness, and injectable manufacturing capability.
• Giapreza competes primarily with established vasopressors on clinical positioning, cost, familiarity, and hospital workflow.
• The commercial market is specialized, but a hospital-ready presentation could improve adoption and reduce pharmacy waste.

FAQs

Can Giapreza be reformulated without changing its active ingredient?

Yes. A sponsor could pursue a new concentration, container, surfactant system, premixed bag, or administration device while retaining angiotensin II acetate. The regulatory burden would depend on the extent of the change.

Is polysorbate 80 the main excipient opportunity in Giapreza?

It is the most technically sensitive excipient because of peptide adsorption, aggregation, peroxide formation, and compatibility concerns. A replacement would need strong comparative data and a clear commercial benefit.

Could a ready-to-use Giapreza bag support premium pricing?

Potentially. The strongest justification would be reduced pharmacy preparation, fewer dosing calculations, lower vial waste, improved dose consistency, and validated stability in the hospital environment.

Does Giapreza have biosimilar risk?

No conventional biosimilar pathway applies because Giapreza is a synthetic peptide drug rather than a biologic approved through a biosimilar framework. Competitive risk would more likely arise through an ANDA or another abbreviated injectable pathway, subject to FDA requirements.

What is the most defensible IP strategy for a Giapreza formulation?

The strongest strategy would combine formulation, packaging, administration-line compatibility, and manufacturing claims tied to measurable performance. Claims limited to common excipients such as mannitol or polysorbate 80 would generally be easier to design around.

References

1. U.S. Food and Drug Administration. (2017). Giapreza (angiotensin II) injection: Prescribing information. FDA.

2. Khanna, A., English, S. W., Wang, X. S., Ham, K., Tumlin, J., Szerlip, H., Busse, L. W., Macias, W. L., Wilson, J., & Tumlin, J. A. (2017). Angiotensin II for the treatment of vasodilatory shock. New England Journal of Medicine, 377(5), 419-430. https://doi.org/10.1056/NEJMoa1704154

3. Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., McIntyre, L., Ostermann, M., Prescott, H. C., Schorr, C., Simpson, S., Wiersinga, W. J., Alshamsi, F., Angus, D. C., Arabi, Y., Azevedo, L., Beale, R., Beilman, G., ... Levy, M. (2021). Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Medicine, 47, 1181-1247. https://doi.org/10.1007/s00134-021-06506-y

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. Innoviva, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.